Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Characterization of Recombinant, Soluble β-Secretase from an Insect Cell Expression System

William D. Mallender, Debra Yager, Luisa Onstead, Michael R. Nichols, Christopher Eckman, Kumar Sambamurti, Lisa M. Kopcho, Jovita Marcinkeviciene, Robert A. Copeland and Terrone L. Rosenberry
Molecular Pharmacology March 2001, 59 (3) 619-626; DOI: https://doi.org/10.1124/mol.59.3.619
William D. Mallender
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra Yager
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luisa Onstead
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Nichols
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Eckman
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kumar Sambamurti
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa M. Kopcho
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jovita Marcinkeviciene
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Copeland
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terrone L. Rosenberry
1 2
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The β-site amyloid precursor protein-cleaving enzyme (BACE) cleaves the amyloid precursor protein to produce the N terminus of the amyloid β peptide, a major component of the plaques found in the brains of Alzheimer's disease patients. Sequence analysis of BACE indicates that the protein contains the consensus sequences found in most known aspartyl proteases, but otherwise has only modest homology with aspartyl proteases of known three-dimensional structure (i.e., pepsin, renin, or cathepsin D). Because BACE has been shown to be one of the two proteolytic activities responsible for the production of the Aβ peptide, this enzyme is a prime target for the design of therapeutic agents aimed at reducing Aβ for the treatment of Alzheimer's disease. Toward this ultimate goal, we have expressed a recombinant, truncated human BACE in a Drosophila melanogasterS2 cell expression system to generate high levels of secreted BACE protein. The protein was convenient to purify and was enzymatically active and specific for cleaving the β-secretase site of human APP, as demonstrated with soluble APP as the substrate in novel sandwich enzyme-linked immunosorbent assay and Western blot assays. Further kinetic analysis revealed no catalytic differences between this recombinant, secreted BACE, and brain BACE. Both showed a strong preference for substrates that contained the Swedish mutation, where NL is substituted for KM immediately upstream of the cleavage site, relative to the wild-type sequence, and both showed the same extent of inhibition by a peptide-based inhibitor. The capability to produce large quantities of BACE enzyme will facilitate protein structure determination and inhibitor development efforts that may lead to the evolution of useful Alzheimer's disease treatments.

Footnotes

    • Received September 21, 2000.
    • Accepted December 1, 2000.
  • Send reprint requests to: Dr. Terrone L. Rosenberry, Department of Pharmacology and Program in Neuroscience, Mayo Foundation for Medical Education and Research, Mayo Clinic Jacksonville, Jacksonville, FL 32224. E-mail address: rosenberry{at}mayo.edu

  • ↵1 Current address: Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 59 (3)
Molecular Pharmacology
Vol. 59, Issue 3
1 Mar 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Recombinant, Soluble β-Secretase from an Insect Cell Expression System
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Characterization of Recombinant, Soluble β-Secretase from an Insect Cell Expression System

William D. Mallender, Debra Yager, Luisa Onstead, Michael R. Nichols, Christopher Eckman, Kumar Sambamurti, Lisa M. Kopcho, Jovita Marcinkeviciene, Robert A. Copeland and Terrone L. Rosenberry
Molecular Pharmacology March 1, 2001, 59 (3) 619-626; DOI: https://doi.org/10.1124/mol.59.3.619

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Characterization of Recombinant, Soluble β-Secretase from an Insect Cell Expression System

William D. Mallender, Debra Yager, Luisa Onstead, Michael R. Nichols, Christopher Eckman, Kumar Sambamurti, Lisa M. Kopcho, Jovita Marcinkeviciene, Robert A. Copeland and Terrone L. Rosenberry
Molecular Pharmacology March 1, 2001, 59 (3) 619-626; DOI: https://doi.org/10.1124/mol.59.3.619
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics